Skip to content

New York Stock Exchange (NYSE) · Healthcare

Johnson & Johnson JNJ

MonitorScore band: 50–60

Last evaluation
2026-09-06
Deep report
no deep report yet

Vote for the next deep dive. This ticker has no full report yet. Subscribers vote on which candidate gets one next. Vote now →

Read it yourself

Step five of the method is the reader's: open the latest annual or quarterly report and read it before acting on anything here. A score is a summary, and a summary is not understanding.

Filings at SEC EDGAR →

Next report expected 2026-10-13.

Price, one year

up daydown day

Daily bars for the last year, drawn relative to the latest close, with no price axis. The shape of the year, not a price.

DCF valuation range

range of the DCF modelsbase casetoday's price

Valuation range, shape only. Figures in the full version.

Monte Carlo outcome shape

Simulated outcome shape, no figures in the free version.

Where the money goes

97.9BRevenue31.4BCost of revenue66.5BGross profit · 68%40.2BOperating expenses26.2BOperating income · 27%5.21BOther & tax21.0BNet income · 21%

Last four reported quarters, 2025-09 → 2026-06, in USD. Filings data as gathered on 2026-09-02. Figures rounded to three significant digits.

Evaluation history

DateVerdict
2026-07-12Monitor
2026-07-13Monitor
2026-09-06Monitor

Want a report on this one?

No deep report has been written for this company yet. Subscribers get one full report a week by email and vote on which candidate is read next.